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Objectives This study sought to assess the vascular response of overlapping Absorb stents com-
pared with overlapping newer-generation everolimus-eluting metallic platform stents (Xience V [XV])
in a porcine coronary artery model.
Background The everolimus-eluting bioresorbable vascular scaffold (Absorb) is a novel approach to
treating coronary lesions. A persistent inﬂammatory response, ﬁbrin deposition, and delayed endo-
thelialization have been reported with overlapping ﬁrst-generation drug-eluting stents.
Methods Forty-one overlapping Absorb and overlapping Xience V (XV) devices (3.0  12 mm) were
implanted in the main coronary arteries of 17 nonatherosclerotic pigs with 10% overstretch. Im-
planted coronary arteries were evaluated by optical coherence tomography (OCT) at 28 days (Ab-
sorb n  11, XV n  7) and 90 days (Absorb n  11, XV n  8), with immediate histological evalua-
tion following euthanasia at the same time points. One animal from each time point was evaluated
with scanning electron microscopy alone. A total of 1,407 cross sections were analyzed by OCT and
148 cross sections analyzed histologically.
Results At 28 days in the overlap, OCT analyses indicated 80.1% of Absorb struts and 99.4% of XV
struts to be covered (p  0.0001), corresponding to histological observations of struts with cellular cover-
age of 75.4% and 99.6%, respectively (p  0.001). Uncovered struts were almost exclusively related to
the presence of “stacked” Absorb struts, that is, with a direct overlay conﬁguration. At 90 days, overlap-
ping Absorb and overlapping XV struts demonstrated 99% strut coverage by OCT and histology, with
no evidence of a signiﬁcant inﬂammatory process, and comparable % volume obstructions.
Conclusions In porcine coronary arteries implanted with overlapping Absorb or overlapping XV struts,
strut coverage is delayed at 28 days in overlapping Absorb, dependent on the overlay conﬁguration of
the thicker Absorb struts. At 90 days, both overlapping Absorb and overlapping XV have comparable
strut coverage. The implications of increased strut thickness may have important clinical and design con-
siderations for bioresorbable platforms. (J Am Coll Cardiol Intv 2013;6:523–32) © 2013 by the American
College of Cardiology Foundation
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524Everolimus-eluting bioresorbable vascular scaffolds (Ab-
sorb, Abbott Vascular, Santa Clara, California) are a novel
approach to treating coronary lesions, in that they provide
transient vessel support and drug delivery to the vessel wall,
without the long-term limitations of standard metallic
drug-eluting stents (DES), such as metallic caging. Unlike
with permanent metallic stenting, the Absorb will potentially
allow for future surgical revascularization, expansive remodel-
ing, restoration of reactive vasomotion, and reliable noninva-
sive imaging of coronary arteries with multislice computed
tomography (1–4). Given the temporary presence of the
Absorb, the small, but potentially fatal, risk of late or very late
stent thrombosis associated with conventional metallic plat-
form DES, may be reduced or even eliminated (5,6).
First-generation DES, namely overlapping sirolimus-
eluting and paclitaxel-eluting stents, have previously been
demonstrated in pre-clinical models to show evidence of a
persistent inflammatory response, fibrin deposition, and
delayed endothelialization (7,8). The purpose of this study
is to assess the vascular response
of overlapping Absorb compared
to the overlapping newer gener-
ation everolimus-eluting metal-
lic platform stents (Xience V
[XV], Abbott Vascular) in a por-
cine coronary artery model.
Methods
Experimental studies received
protocol approval from the insti-
tutional animal care and use
committee and were conducted
in accordance with American
Heart Association guidelines for
pre-clinical research and the Guide for the Care and Use of
aboratory Animals (National Institutes of Health, 2010).
Seventeen healthy, nonatherosclerotic Yorkshire-Landrace
swine were implanted via femoral access according to
standard procedures (9). Each animal was implanted with
overlapping 3.0  12.0-mm Absorb or XV stents in up to
of the main coronary vessels according to a pre-
etermined matrix of randomization. A maximum of 2
verlapping Absorb and 1 overlapping XV were permitted
er animal. The Absorb and XV sizes were matched to the
essel size at a target balloon-to-artery ratio of 1.1 to 1.0
10% overstretch). In total, 17 animals (41 vessels) were
Corporation, Cordis Corporation, and BioSensors International; and is a consultant
for Medtronic AVE, Abbott Vascular, W.L. Gore, Atrium Medical, Arsenal
Medical, and Lutonix. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
EEL  external elastic
lamina
IQR  interquartile range
OCT  optical coherence
tomography
SA ratio  scaffold/stent to
artery ratio
SEM  scanning electron
microscopy
XV  Xience V stent(s)Manuscript received November 14, 2012; revised manuscript received December 3,
2012, accepted December 21, 2012.mplanted with overlapping Absorb or overlapping XV.
ight and 9 pigs underwent follow-up at 28 days (Absorb
 12, XV n  8), and 90 days (Absorb n  12, XV n 
), respectively (Online Appendix). These time points have
een reported to be representative of peak neointimal
rowth in humans at 6 months (28 days) and 18 months (90
ays) (10). Coronary angiography and OCT analyses were
erformed at baseline and at both time points. One animal
rom each of the 28 and 90 day time points was excluded
rom OCT and histological analyses, and implanted arteries
valuated with scanning electron microscopy (SEM) alone.
ll pigs were humanely euthanized at follow-up immedi-
tely after angiography (SEM) or OCT (all others).
OCT analyses. OCT evaluation of the Absorb and XV
overlap were performed at a pullback speed of 1.0 mm/s at
baseline and at follow-up, utilizing a commercially available
time-domain OCT system (M3 System, LightLab Imag-
ing, Westford, Massachusetts). The image wire was passed
distal to the treated vessel without the conventional support
of the balloon occlusion catheter to minimize the risk of
disrupting the endothelial coverage in the treated vessel.
Bolus doses of Ringer’s lactate were used to clear blood
distal to the inflated occlusion balloon in the proximal
vessel, and OCT pullbacks were initiated. Quantitative and
qualitative analyses were performed with proprietary soft-
ware for off-line analysis (LightLab Imaging). With adjust-
ment for pullback speed, analyses of continuous cross
sections were performed at 1-mm longitudinal intervals
consistent with previously validated methodologies (Online
Appendix) (1,11,12). OCT analyses were performed by a
team of physicians and analysts of an independent core
laboratory (Cardialysis BV, the Netherlands). Specifically
for the overlapping Absorb, struts were defined by their
overlay configuration, namely “stacked inner,” “stacked
outer,” and “other” (i.e., without a clear direct overlay
configuration) (Fig. 1) (13). The threshold for coverage of
the Absorb strut is 30 m, corresponding to the average
interobserver measurement (difference in 300 struts ana-
lyzed 2 times, 35  6 m) of the endoluminal light
ackscattering strut boundary (14). To allow full visualization
f the spatial distribution of strut coverage struts in the
verlapping devices, “spread-out-vessel graphs”—a visual rep-
esentation of the vessel as if it had been cut along the reference
ngle (0°) and spread out on a flat surface—were created based
pon previously described methodologies (11).
Histological analyses and SEM. Histological analyses are de-
cribed in the Online Appendix. SEM was performed with a
itachi Model 3600N scanning electron microscope (Hitachi,
okyo, Japan). Sections were stained with hematoxylin and
osin and elastic van Gieson or Movat pentachrome.
Statistical analyses. Continuous variables are reported as
mean  SD, categorical variables as counts (%). Compari-
sons were made with the Student t test/Mann-Whitney U
test and chi-square/Fisher exact test as appropriate. Tissue
minal
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525coverage was estimated through the proportion of uncov-
ered struts (dichotomous variable), distribution curves, and
areas (continuous variable). Strut-level data were analyzed
(dichotomous or continuous variables) using multilevel lo-
gistic regression models with random effects at 4 different
levels: 1) treatment arm; 2) animal; 3) vessel; and 4) strut.
All statistical tests were 2 tailed, and a value of p 0.05 was
considered statistically significant. Analyses were conducted
Figure 1. Examples of Absorb Struts According to Their Overlay Configurat
“Stacked inner,” “stacked outer,” and “other” struts are illustrated on optical coher
gray arrows indicate “stacked inner” struts with corresponding “stacked outer” st
each other or lying within 1 strut width of each other. Blue arrows indicate “othe
Gray arrow indicates a strut attached to a platinum marker used to visualize the
Absorb struts where the neointimal coverage is measured from (mid part of the lu
Table 1. Results of the OCT Analysis at 28 and 90 Days (2 Separate Anim
Absorb*
Overlap Nonoverlap p
28 days
Coverage, categorical 1,215 (80.1%) 908 (98.2%) 
Neointimal area, mm2 2.80 0.51 2.29 0.49
Mean lumen area, mm2 5.44 0.76 5.11 0.68
Mean scaffold area, mm2 8.80 0.75 7.68 0.75
% Volume obstruction 31.30 5.47 29.85 5.66
90 days
Coverage, categorical 1,304 (99.5%) 838 (99.8%)
Neointimal area, mm2 3.84 0.74 2.43 1.02 
Mean lumen area, mm2 4.28 1.36 4.62 1.22
Mean scaffold area, mm2 9.01 0.56 7.32 1.96
% Volume obstruction 42.12 8.02 28.91 13.09
Values are n (%) or mean  SD. Comparisons between overlap and nonoverlap territories for the
coverage is 30 m. †XV threshold for coverage is 0 m. ‡p Value comparing overlapping Absorb vN/A not applicable; XV Xience V.using SAS System Software version 9.2 (SAS Institute,
Cary, North Carolina).
Results
All overlapping devices were successfully deployed under
angiographic guidance, and all 17 animals remained healthy
for the duration of the experiment. The mean overlap length
the Overlap
omography (OCT) (left) and scanning electron microscopy (right). White and
cated abluminally—deﬁned as struts with a direct overlay conﬁguration with
s,” i.e., struts in the overlap without a clear direct overlay conﬁguration. The
during implantation. The broken white lines illustrate selected examples of
side of “black core” area of the Absorb strut) to the lumen boundary.
ups) in the Overlap Porcine Study 
XV†
Overlap
p Value‡Overlap Nonoverlap p Value
833 (99.4%) 984 (99.8%) 0.33 0.0001
2.14 0.39 1.74 0.23 0.037 0.01
4.87 1.01 4.80 1.08 0.90 0.19
7.01 0.96 6.54 1.08 0.27 0.001
31.01 7.47 27.62 4.92 0.34 0.93
932 (100.0%) 923 (100.0%) N/A N/A
2.73 0.81 2.14 0.66 0.13 0.005
4.52 1.79 4.66 1.52 0.87 0.73
7.26 1.19 6.80 1.08 0.44 0.006
39.40 15.57 33.27 13.58 0.42 0.64
and XV individually are shown, with further comparisons between devices. *Absorb threshold for
verlapping XV.ion in
ence t
ruts lo
r strut
Absorbal Gro
Value
0.0001
0.028
0.31
0.002
0.55
0.26
0.001
0.54
0.056
0.013
Absorb
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r
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526at 28 days (Absorb 5.16  1.34 mm, XV 5.42  2.44 mm,
 0.76) and 90 days (Absorb 4.82  1.77 mm, XV 5.45 
1.73 mm, p  0.43) did not significantly differ between
devices. Median scaffold/stent to artery ratio (SA ratio) for the
proximal (Absorb SA ratio 1.13 [interquartile range (IQR):
1.06 to 1.18]; XV SA ratio 1.19 [IQR: 1.15 to 1.23], p 0.19)
and distal (Absorb SA ratio 1.09 [IQR: 1.02 to 1.13]; XV SA
ratio 1.14 [IQR: 1.12 to 1.18], p 0.052) overlapping Absorb
or overlapping XV did not significantly differ.
OCT ﬁndings. In total, 15,026 struts in 1,407 cross sections
were analyzed. All overlapping devices were fully interro-
gated with OCT and were of adequate image quality. Table 1
indicates the OCT findings. Representative OCT images
(Fig. 2) and spread-out-vessel graphs (Fig. 3) are illustrated.
At 28 days, strut coverage in the overlapping versus non-
overlapping Absorb segments was significantly delayed
(80.1% vs. 98.2%, p  0.0001) and to the overlapping XV
Figure 2. Representative Appearances of Overlapping Absorb and Overlapp
Note the uncovered “stacked inner” struts of the Absorb at 28 days, which wasegment (99.4%, p  0.0001). At 90 days, both overlapping wAbsorb and overlapping XV devices demonstrated 99%
strut coverage.
Arterial (neointimal) response. Figure 4 illustrates the neo-
ntimal distribution curves for the overlapping devices at 28
nd 90 days. Table 2 indicates the heterogeneity in the
eointimal coverage dependent on the overlay configuration
f the Absorb struts. At 28 days, neointimal responses
ndicated a significantly greater neointimal area in the
verlap of both devices compared with the nonoverlap
egments (Table 1). This despite the Absorb having reduced
inary strut coverage at the overlap. A bimodal neointimal
esponse, secondary to a separate neointimal response for the
stacked inner” and “stacked outer” struts (neointimal coverage:
stacked inner” struts 76  68 m vs. “stacked outer” struts
40 71 m, p 0.0001), was evident (Fig. 4), with “stacked
nner” Absorb struts primarily responsible for noncovered
truts. The mean scaffold area of the overlapping Absorb
Devices by OCT at 28 and 90 Days
evident at 90 days. OCT  optical coherence tomography; XV  Xience V.ing XVas significantly greater compared with the nonoverlap-
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527ping Absorb and to the overlapping XV, which translated
into comparable % volume obstructions for vessels im-
planted with either overlapping device (p  0.93).
At 90 days, a significantly greater neointimal area (p 
0.001) and % volume obstruction (p  0.013) was seen in
the Absorb overlap compared with the Absorb nonoverlap
(Table 1). As evident at 28 days, the mean scaffold area was
greater in the Absorb overlap compared with the nonover-
lap, which translated into a comparable % volume obstruc-
tion at the overlap between the Absorb or XV (p  0.64).
Histological and SEM ﬁndings. In total, 148 histology cross
sections were analyzed. Representative histology cross
sections (Fig. 5) and SEM (Figs. 6 and 7) at 28 and 90
days for each overlapping device are shown. At all time points,
the injury scores were comparable between the overlap and
nonoverlap and between devices. The Online Appendix pro-
vides the full histomorphometric and qualitative histomorpho-
Figure 3. “Spread-Out-Vessel Graphs” Representing the Spatial Distribution
Overlapping XV Device at 28 and 90 Days
The longitudinal distance from the distal edge of the overlapping devices to t
the struts are located in the circular cross-section with respect to the center o
of noncovered struts and its clustering at the 4 considered levels (treatment a
Horizontal axis (per overlap device) indicates the distance from the distal edge
regions. Vertical axis (per overlap device) indicates the angle where the strut i
vessel (0° to 360°). XV  Xience V.logic findings in the overlap and nonoverlap.Histology indicated reduced cellular strut coverage of the
Absorb at 28 days (75.4 16.4%), and broadly corroborated
the OCT findings of coverage (80.1%). The internal and
external (EEL) elastic lamina areas were significantly
greater in the Absorb overlap compared with the Absorb
nonoverlap at 28 days (EEL overlap 9.89  1.02 mm2 vs.
EL nonoverlap 8.95  0.77 mm2, p  0.004) and 90
days (EEL overlap 10.60  2.01 mm2 vs. EEL nonover-
ap 9.29  1.48 mm2, p  0.005). At 90 days, the %
olume obstruction did not significantly differ between the
verlapping Absorb and overlapping XV (47.90  14.37%
s. 37.78  16.97%, p  0.18).
iscussion
The main findings of this study are that: 1) in a porcine
coronary artery model, the neointimal coverage of overlap-
e Noncovered Struts Along Each Overlapping Absorb or
t (horizontal axis per overlapping device) is correlated to the angle where
ity of the vessel (vertical axis per overlapping device). The spatial distribution
imal, vessel, and strut) are illustrated. Red dots represent uncovered struts.
e implanted devices to the struts in the overlapping and nonoverlapping
ed in the circular cross-section with respect to the center of gravity of theof th
he stru
f grav
rm, an
of th
s locatping Absorb struts is delayed at 28 days, and resolves at 90
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528days; 2) there was a bimodal neointimal response in the
overlapping Absorb at 28 days (and not 90 days), with
Absorb struts with a direct overlay configuration to each
other (i.e., ‘stacked’ struts), almost exclusively responsible
Figure 4. Distribution of Neointimal Coverage for the Overlapping Absorb a
Distribution curves for the Absorb at 28 days indicated 2 distribution curves, “
tive of a bimodal neointimal response. XV  Xience V.for the reduced cellular coverage; 3) despite the neointimalresponse being greater with the Absorb, this did not
translate into a significant difference in % volume obstruc-
tion for either overlapping device by OCT, at both time
points; and 4) the increased strut thickness of the Absorb
erlapping XV at 28 Days and 90 Days
d inner” (broken red line) and “stacked outer” (broken green line), indica-nd Ov
stacke(156 m) is likely to be the main mechanism for the
ts
a
(
i
s
Values are n (%) or mean SD. *Absorb threshold for coverage is 30 m.
rome stain) days.
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529reduced binary coverage of overlapping Absorb struts at 28
days, compared with the thinner XV struts (88.6 m).
Strut thickness. Given the similarities between the Absorb
and XV, both with biocompatible coatings (bioresorbable or
biostable polymers) and low/comparable inflammatory re-
sponses, similar vessel injury scores and everolimus release
kinetics—essential to the prevention of restenosis after
vessel injury (15,16)—it is likely that the increased strut
thickness (156 m) of the Absorb lead to a greater neoin-
imal response compared with the thinner-strut (88.6 m)
XV. This is supported by historical findings of increased
strut thickness of bare-metal stents being associated with
greater angiographic and clinical restenosis (17,18). Within
the DES era, the clinical implications of strut thickness have
been more variable, due to the complex relationship be-
tween the strut material and characteristics, stent design,
polymer type and antiproliferative drug release kinetics
(16,19). The findings from SCAAR (the Swedish Coronary
Angiography and Angioplasty Registry) (20) (n  35,000)
have provided clarity to this issue, with the thinner-strut
(117 m) Taxus Liberté (Boston Scientific, Natick, Mas-
achusetts) shown to have a mild, but significantly, reduced
djusted risk of restenosis compared with the thicker-strut
154 m) Taxus Express. Notably, both devices had an
dentical polymer matrix, the same drug release kinetics, and
imilar metallic platforms. It is therefore not inconceivable
y at the time points of 28 (elastic van Gieson stain) and 90 (Movat pentach-Table 2. Neointimal Strut Coverage (Categorical) by Type of Absorb Strut
Overlap* Nonoverlap* p Value
28 days
Coverage, categorical
All vs. all 1,215 (80.1%) 908 (98.2%) 0.0001
Stacked inner vs. all 286 (54.1%) — 0.0001
Stacked outer vs. all 521 (99.4%) — 0.036
Other vs. all 408 (88.1%) — 0.0001
Coverage, m
All vs. all 155 104 150 73 0.028
Stacked inner vs. all 76 68 — 0.0001
Stacked outer vs. all 240 71 — 0.0001
Other vs. all 148 93 — 0.76
90 days
Coverage, categorical
All vs. all 1,304 (99.5%) 838 (99.8%) 0.26
Stacked inner vs. all 397 (99.3%) — 0.15
Stacked outer vs. all 446 (99.6%) — 0.48
Other vs. all 461 (99.6%) — 0.61
Coverage, m
All vs. all 314 143 211 98 0.0001
Stacked inner vs. all 257 124 — 0.0001
Stacked outer vs. all 402 124 — 0.0001
Other vs. all 280 136 — 0.0001Figure 5. Representative Histology Appearances
Representative appearances of overlapping Absorb and Xience V devices by histolog
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530that the increased strut thickness of first-generation DES
may have contributed to the delayed strut coverage reported
in previous animal studies, in addition to the prolonged
inflammatory process (7,21).
The mechanism of thicker struts leading to a greater
neointimal response, particularly with the “stacked” Absorb
struts (approximately 300 m), is probably related to the
ole of wall shear stress in modulating the neointimal
esponse. Thicker, rectangular (non-streamlined) struts,
haracteristic of the Absorb, may theoretically increase the
evice area exposed to low endothelial oscillatory shear stress
reas, leading to the local accumulation of growth factors,
itogenic cytokines, and platelets, which promote neointimal
ormation until a smooth lumen surface is achieved (22,23).
Figure 6. SEM of Overlapping Absorb and Overlapping XV at 28 Days and 9
At 28 days, the Absorb was partially covered by a thin layer of neointima, with
halves of the vessel); the Xience V (XV) overlap appeared completely covered
At 90 days, based on these single cases of overlapping Absorb (E, single half o
appeared to be fully complete. SEM  scanning electron microscopy.he process of having to fully cover 300 m of overlappingAbsorb struts is therefore the likely primary reason for the
delayed coverage at 28 days, despite the increased neointima
associated with the thicker struts. At 90 days, this process is
complete. Within the first month, the Absorb elutes 80% of
the antiproliferative (everolimus) drug (24) and would substan-
tially suppress the neointimal process. Thereafter, a smaller
amount of drug is eluted, leading to a more attenuated effect
(compared with the first month) on the synthetic phenotype of
neointimal smooth muscle cells (SMC), and thereby its
matrix-producing capacity.
Comparison of overlapping Absorb and XV devices. Despite
comparable injury scores in vessels treated with either
device, the overlapping Absorb exhibited a greater neointi-
mal response in absolute terms compared to the nonover-
ys
y uncovered struts in the overlapping mid-region (A and C represent both
mildly thickened neointima (B and D represent both halves of the vessel).
el) and overlapping XV (F, single half of vessel), re-endothelialization0 Da
man
with a
f vesslapping Absorb segments. This, however, did not trans-
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531late into a significantly greater relative % volume
obstruction between either device on OCT analyses, due
to a greater vessel/scaffold area associated with the
Absorb overlap. The latter allowed for the accommoda-
tion of the increased neointima area associated with the
overlapping Absorb.
As to why the overlapping Absorb had a greater
scaffold/EEL area, it is likely that the addition of
overlapping Absorb struts on either side of the deploying
device balloon increased the vessel size by 4 layers of
Absorb struts (600 m thickness), without rupturing
he internal elastic lamina and vessel media. In addition,
he more conformable, thicker Absorb struts (compared
ith metal) (25) may have reduced its “cutting effect”
hen embedded in the vessel media, without any resul-
ant increase in vessel injury. Conversely, previous pre-
linical studies have shown that overstretching of the
essel can induce mechanical injury to neointimal SMCs,
eading to changes in synthetic SMC phenotypes, with a
Figure 7. Magnified SEM Views of Overlapping Absorb
Magniﬁed scanning electron microscopy (SEM) view of the overlapping
Absorb at 28 days (upper), demonstrating multiple uncovered Absorb
struts primarily secondary to the direct overlay conﬁguration of the
“stacked inner” struts (white asterisks) to the corresponding “stacked
outer” struts located abluminally. At 90 days (lower), all “stacked inner”
struts (white asterisks) are covered.esultant increase in constrictive remodeling (26). Theossibility of a greater neointimal response associated
ith high-grade stenotic lesions treated with overlapping
bsorb can therefore not be excluded, as previously
eported in 1 clinical study (27).
Implications for current and future bioresorbable devices.
Practical clinical advice for Absorb implantation should
therefore include using longer devices to avoid implant-
ing overlapping devices, possible avoidance of overlapping
the device at a stenotic lesion as previously discussed, and
using design features consisting of radio-opaque markers to
allow for fluoroscopic positioning of the devices to minimize
or obviate the need to overlap, as reported in previous bench
studies (13). Importantly antiplatelet therapy should not be
prematurely discontinued, and patients should be monitored
closely to ensure compliance.
Study limitations. The nonatherosclerotic porcine model is
limited by its ability to replicate conditions in atheroscle-
rotic human coronary arteries, although the porcine model
at 28 and 90 days is classically suggested to be representative
of 6- and 18-month peak neointimal growth, respectively,
in humans (10). Given the 90-day follow-up in the porcine
model, the potential late beneficial effects of bioresorption
of the Absorb (5) could not be accounted for in the porcine
model. In addition, the possibility of an adaptive expansive
remodeling process, with the prospect of “late luminal
enlargement,” may occur as early as 1 year following partial
bioresorption and expected loss of structural integrity of the
Absorb device, and may prove to be of additional clinical
value (5,28). In view of the delayed cellular coverage of
overlapping Absorb struts at 28 days, the duration of
antiplatelet therapy required for overlapping Absorb devices
cannot be clearly inferred from the present pre-clinical study
and requires further clinical investigation.
Conclusions
In porcine coronary arteries implanted with overlapping
Absorb or overlapping XV, strut coverage is delayed at 28
days in overlapping Absorb, dependent on the overlay
configuration of the thicker Absorb struts. At 90 days,
comparable strut coverage and % volume obstruction were
evident with either overlapping device. The implications of
increased strut thickness and delayed coverage, may have
important clinical (e.g., avoiding or minimizing the length
of the overlap, duration of antiplatelet therapy), and design
considerations (e.g., longer device lengths and the require-
ment of dedicated bifurcation devices to avoid overlapping
the device) for current and future bioresorbable platform
devices.
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APPENDIX
For expanded Methods, Results, and Discussion sections, please see the
online version of this paper.
